Clinical utility of antifungal susceptibility testing

Area of Science:

• Medical Mycology
• Infectious Diseases
• Antimicrobial Resistance

Background:

• Invasive fungal diseases (IFDs) contribute significantly to patient morbidity and mortality.
• Immunocompromised individuals are particularly vulnerable to IFDs.
• Emerging antifungal resistance poses a critical challenge in clinical management.

Purpose of the Study:

• To review the current landscape of antifungal susceptibility testing (AST) for pathogenic fungi.
• To highlight the clinical utility and limitations of available resistance data.
• To discuss the implications of resistance data for guiding antifungal therapy and predicting patient outcomes.

Main Methods:

• Comprehensive literature review of studies on antifungal susceptibility testing in pathogenic yeasts and moulds.
• Analysis of existing data on antifungal resistance mechanisms and trends.
• Evaluation of the strengths and weaknesses of current AST methodologies and interpretation guidelines.

Main Results:

• Significant variability exists in performing and interpreting fungal AST compared to bacterial AST.
• Current resistance data offers valuable insights but has notable limitations for clinical decision-making.
• Understanding resistance patterns is crucial for effective treatment selection and prognosis.

Conclusions:

• Standardized and reliable antifungal susceptibility testing is essential for combating resistant fungal infections.
• Further research is needed to refine AST methods and interpretation standards for clinical application.
• Improved resistance data will enhance the ability to guide antifungal treatment and improve patient outcomes.